Work

The value of PSMA PET for risk stratification in prostate cancer: an update and future aspects

Year: 2025

Type: article

Abstract: PSMA-PET has become a pivotal imaging method for staging and restaging of prostate cancer. Risk stratification of the disease is a crucial for the patients to receive most appropriate treatment, and for the clinicians to follow the patients more precisely. PSMA-PET provides non-invasive biomarkers for the risk assessment of prostate cancer, offering prediction of clinical outcomes. PROMISE criteria have been developed as comprehensive and integrated framework demonstrating association with overall survival. In this review, we aim to provide a brief update of the prognostic value of PSMA-PET for risk assessment in prostate cancer.

Source: Seminars in Nuclear Medicine

DOI: 10.1053/j.semnuclmed.2025.12.003

Authors: Caner Civan, Madeleine J. Karpinski, Kambiz Rahbar, Wolfgang P. Fendler, Ken Herrmann

Institutions: Essen University Hospital, University Hospital Münster, Deutsches Konsortium für Translationale Krebsforschung

Language: English

Topic: Prostate Cancer Diagnosis and Treatment

Subfield: Pulmonary and Respiratory Medicine

Field: Medicine

Domain: Health Sciences

SDG: Good health and well-being

Open Access status: hybrid

Estimated APC paid: $5,090